Acquisition of a BRAF fusion has recently been described as a novel mechanism of acquired resistance to vemurafenib in a patient with BRAF V600E melanoma, underlining the key role of this oncogenic activation in cancer survival [86]. This evidence concerns the gene BRAF and cancer.